FORMULATION AND EVALUATION OF GLIMEPIRIDE 4 MG. SUSTAINED RELEASE TABLETS
Fuente:
Zenodo
Salvato in:
| Autore principale: | |
|---|---|
| Natura: | Recurso digital |
| Lingua: | inglese |
| Pubblicazione: |
Zenodo
2026
|
| Accesso online: | |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
|
| _version_ | 1866901802318823424 |
|---|---|
| author | Dr. Vinod D. Usnale1*, Ms. Nila Priti Baswaraj1, Patel Kaif Altaf1, Palak Devi1, Pandhare Payal Sunil1, Murkute Vishwajeet Vilas1 |
| author_facet | Dr. Vinod D. Usnale1*, Ms. Nila Priti Baswaraj1, Patel Kaif Altaf1, Palak Devi1, Pandhare Payal Sunil1, Murkute Vishwajeet Vilas1 |
| contents | <p><span>The present study was aimed at the formulation and evaluation of Glimepiride 4 mg sustained release tablets to enhance therapeutic efficacy and improve patient compliance. Glimepiride, a third-generation sulfonylurea, is widely used in the treatment of Type 2 Diabetes Mellitus. Due to its short biological half-life and requirement for prolonged glycemic control, sustained release formulations were developed using hydrophilic polymers such as HPMC K100M and carbapol 934P. The SR- Tablets were prepared by wet granulation method and evaluated for pre-compression and post-compression parameters. And In-vitro dissolution studies were performed for 12 hours, and release kinetics were analyzed. The optimized formulation showed controlled drug release with good physicochemical properties, indicating suitability for sustained release therapy.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_19592142 |
| institution | Zenodo |
| language | eng |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | FORMULATION AND EVALUATION OF GLIMEPIRIDE 4 MG. SUSTAINED RELEASE TABLETS Dr. Vinod D. Usnale1*, Ms. Nila Priti Baswaraj1, Patel Kaif Altaf1, Palak Devi1, Pandhare Payal Sunil1, Murkute Vishwajeet Vilas1 <p><span>The present study was aimed at the formulation and evaluation of Glimepiride 4 mg sustained release tablets to enhance therapeutic efficacy and improve patient compliance. Glimepiride, a third-generation sulfonylurea, is widely used in the treatment of Type 2 Diabetes Mellitus. Due to its short biological half-life and requirement for prolonged glycemic control, sustained release formulations were developed using hydrophilic polymers such as HPMC K100M and carbapol 934P. The SR- Tablets were prepared by wet granulation method and evaluated for pre-compression and post-compression parameters. And In-vitro dissolution studies were performed for 12 hours, and release kinetics were analyzed. The optimized formulation showed controlled drug release with good physicochemical properties, indicating suitability for sustained release therapy.</span></p> |
| title | FORMULATION AND EVALUATION OF GLIMEPIRIDE 4 MG. SUSTAINED RELEASE TABLETS |
| url | https://doi.org/10.5281/zenodo.19592142 |